Ortho Clinical Diagnostics Holdings Plc Revenue Growth Rates (OCDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ortho Clinical Diagnostics Holdings Plc  (NASDAQ: OCDX)
 

OCDX's Revenue Growth by Quarter and Year

Ortho Clinical Diagnostics Holdings Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OCDX Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter January -
3rd Quarter October -
2nd Quarter July -
1st Quarter April 500.10
FY 500.10





OCDX Revenue first quarter 2022 Y/Y Growth Comment
Ortho Clinical Diagnostics Holdings Plc reported decrease in Revenue in the first quarter 2022 by -1.32% to $ 500.10 millions, from the same quarter in 2021.
The decrease in the first quarter 2022 Ortho Clinical Diagnostics Holdings Plc's Revenue compares unfavorably to the Company's average Revenue increase of 12.41%.

Looking into first quarter 2022 results within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Revenue growth. While Ortho Clinical Diagnostics Holdings Plc' s Revenue decline of -1.32% ranks overall at the positon no. 3377 in the first quarter 2022.


OCDX Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter January - 0.83 % - -
3rd Quarter October - 15.83 % - -
2nd Quarter July - 26.12 % - -
1st Quarter April -1.32 % 24.25 % - -
FY   - 15.66 % - -

Financial Statements
Ortho Clinical Diagnostics Holdings Plc's first quarter 2022 Revenue $ 500.10 millions OCDX's Income Statement
Ortho Clinical Diagnostics Holdings Plc's first quarter 2021 Revenue $ 506.80 millions Quarterly OCDX's Income Statement


OCDX Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter January - -0.29 % 14.54 % -
3rd Quarter October - 6.09 % 15.52 % -
2nd Quarter July - -2.82 % -4.27 % -
1st Quarter April -4.01 % -1.92 % - -
FY (Year on Year)   - 15.66 % - -


Back to OCDX Growth rate Comparisons >> Back to OCDX Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #469
Overall #3377

Revenue Y/Y Growth Statistics
High Average Low
15.66 % 12.41 % 9.17 %
(Jan 02 2022)   (Apr 03 2022)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #469
Overall #3377
Revenue Y/Y Growth Statistics
High Average Low
15.66 % 12.41 % 9.17 %
(Jan 02 2022)   (Apr 03 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Ortho Clinical Diagnostics Holdings Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
15.52 % 2.86 % -4.27 %
(Sep 27 2020)  


OCDX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Ortho Clinical Diagnostics Holdings Plc disclosed fall in Revenue from the fourth quarter by -4.01% to $ 500.10 millions, from $ 521.00 millions achived in the previous reporting period.

But that's not important problem, as Ortho Clinical Diagnostics Holdings Plc's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Ortho Clinical Diagnostics Holdings Plc's Revenue growth quarter on quarter, overall rank is 2836.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #445
Overall #2836
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #445
Overall #2836
Revenue Q/Q Growth Statistics
High Average Low
15.52 % 2.86 % -4.27 %
(Sep 27 2020)  


OCDX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Ortho Clinical Diagnostics Holdings Plc disclosed fall in Revenue from the fourth quarter by -4.01% to $ 500.10 millions, from $ 521.00 millions achived in the previous reporting period.

But that's not important problem, as Ortho Clinical Diagnostics Holdings Plc's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Ortho Clinical Diagnostics Holdings Plc's Revenue growth quarter on quarter, overall rank is 2836.


Ortho Clinical Diagnostics Holdings Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Apr 03 2022)		 12 Months Ending
(Jan 02 2022)		 12 Months Ending
(Oct 03 2021)		 12 Months Ending
(Jul 04 2021)		 12 Months Ending
(Apr 04 2021)
Cumulative Revenue 12 Months Ending $ 2,036.10 $ 2,042.80 $ 0.00 $ 0.00 $ 506.80
Y / Y Revenue Growth (TTM) 9.17 % 15.66 % - - -
Year on Year Revenue Growth Overall Ranking # 2230 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -0.33 % 0.21 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 3377 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Apr 03 2022 period, Ortho Clinical Diagnostics Holdings Plc's cumulative twelve months Revenue were $ 2,036 millions, company would post below average annual Revenue growth of 0.21% year on year, if the fiscal year would end at Apr 03 2022.
A slow-down in the Ortho Clinical Diagnostics Holdings Plc's Revenue growth from the 521% growth in Jan 02 2022.

In the Healthcare sector 320 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2230.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 13
Healthcare Sector # 321
Overall # 2230

Revenue TTM Y/Y Growth Statistics
High Average Low
15.66 %
 12.41 %
9.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 469
S&P 500 # 3377
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Apr 03 2022 period, Ortho Clinical Diagnostics Holdings Plc's cumulative twelve months Revenue were $ 2,036 millions, company would post below average annual Revenue growth of 9.17% year on year, if the fiscal year would end at Apr 03 2022.
A slow-down in the Ortho Clinical Diagnostics Holdings Plc's Revenue growth from the 521% growth in Jan 02 2022.

In the Healthcare sector 320 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2230.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 13
Healthcare Sector # 321
Overall # 2230

Revenue TTM Y/Y Growth Statistics
High Average Low
15.66 %
12.41 %
9.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 469
S&P 500 # 3377




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OCDX's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Apr 03 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Apr 03 2022
Medtronic Plc-1.21%$ -1.209 millions
National Vision Holdings Inc -1.21%$ -1.211 millions
Ortho Clinical Diagnostics Holdings Plc-1.32%$ -1.322 millions
Revvity Inc-3.69%$ -3.689 millions
Envista Holdings Corporation-10.97%$ -10.970 millions
Lakeland Industries Inc -19.99%$ -19.987 millions
Enzo Biochem Inc-20.05%$ -20.048 millions
Ayala Pharmaceuticals Inc -81.82%$ -81.818 millions
Rafael Holdings Inc-92.32%$ -92.323 millions


About Ortho Clinical Diagnostics Holdings Plc Revenue Growth Rates (OCDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ortho Clinical Diagnostics Holdings Plc (CIK 1828443).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-22-008636
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ortho Clinical Diagnostics Holdings Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.